An underground market for unlicensed slimming drugs is propelled by social media fitness personalities and vendors on messaging platforms, based on recent findings.
Experimental Treatment Acquiring Popularity Via Social Media
The experimental drug, which remains in clinical trials, is being promoted by social media influencers for its alleged weight-reducing properties. Followers are urged to contact these profiles directly for supplier links, while also receiving promotional offers.
Active Trade on Messaging Platforms
Separately, a flourishing market exists on Telegram, where communities with numerous of participants share “before and after” images, injection guides and claims of next-day British shipping. Sellers promote the substance there before redirecting buyers to WhatsApp for purchases.
Understanding Retatrutide
This medication is an experimental injection developed by US drugmaker Eli Lilly. The drug affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could assist patients reduce up to 25% of their total weight. Nicknamed the “triple G”, the drug is being promoted digitally as the successor to Ozempic.
Medical Professionals Express Concerns
However, doctors and chemists have cautions that the distribution of what is still an unapproved drug in the United Kingdom is a cause for concern and could lead to individuals administering products of uncertain source.
Some professionals stated the popularity for the experimental drug could be linked to the increasing cost of licensed weight loss treatments such as Mounjaro.
Regulatory Status and Enforcement
Selling retatrutide on TikTok or messaging apps is prohibited in the United Kingdom, as it is an unlicensed medication that must not be promoted or supplied for human use under the Human Medicines Regulations 2012.
Several content creators try to sidestep the regulations by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but advertising and supply can still breach medicines, advertising, and consumer regulations, potentially leading to fines, legal action or prison.
Platform Response and Content Elimination
According to the social media company, the service has removed problematic material and banned related hashtags and query recommendations. The company stated it was committed to keeping the platform safe and allocating resources in enhancing enforcement strategies.
Digital Marketplace Operations
Investigations also found groups with up to nine thousand members selling the experimental drug using Telegram's integrated search feature, which functions like a public directory. Entering “retatrutide” immediately brings up groups with thousands of users, populated with images of slimming results, positive reviews and step-by-step instructions for preparing or injecting at home.
After minutes of joining one group, a vendor posted contact information, where most purchases occur. The seller provided an instruction manual and promised shipping within two days. When questioned whether the product was genuine, one seller responded: “You can’t be sure.” Another shared a image of a alleged laboratory certificate. None asked about weight, health issues or previous experience.
Product Information and Costs
Within these communities, messages show dark colored parcels with Royal Mail labels, claiming to contain fresh supplies. One communication read: “It took eight of us to load them this morning.”
Customers can select between dry substance containers, mixed at residence with sterile water, or ready-to-use pens typically priced at 160 pounds for 20mg. When asked how much time a pen should last, vendors give contradictory responses ranging from a several days to “depends on your body”.
Service Oversight and Security Measures
A spokesperson for Telegram stated it regularly moderated harmful material on its platform including material that promoted the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.
Healthcare Professional Warnings
“People are injecting materials they cannot confirm. Even if the research behind retatrutide is valid, these online products may not include what they claim,” said a pharmacy expert, the head of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of an online medical service connected the increase in demand to recent cost increases for authorized weight-loss drugs such as Mounjaro. “With prices increasing, patients are using social media. But counterfeit treatments are highly risky. You can’t be certain what’s contained or whether the environment they were made in was clean,” she explained.
Her team has previously encountered individuals injured by self-injection from unconfirmed sources. “We recognize the frustration, but buying from Telegram or communication platforms is taking chances with your health,” said the doctor. “These materials could be impure or incorrectly dosed.”
Producer Statement
A representative from Eli Lilly said retatrutide was in phase 3 research studies and had not been evaluated or approved by any regulatory agency globally. “Consequently at this point no one can sell [it] for human use,” they explained, adding that any product “misleadingly claiming itself as a Lilly investigational product not yet authorized … may expose patients to potentially serious medical dangers”.
